174 related articles for article (PubMed ID: 17520185)
1. Patterns of care in the radiotherapy of prostate cancer in Northern Bavaria 1998-2000.
Vordermark D; Marold D; Wirth S; Keilholz L; Pfändner K; Schimpke T; Thiel HJ; Willner J; Ziegler K; Guckenberger M; Flentje M
Strahlenther Onkol; 2007 Jun; 183(6):314-20. PubMed ID: 17520185
[TBL] [Abstract][Full Text] [Related]
2. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer.
Sasaki T; Nakamura K; Shioyama Y; Ohga S; Toba T; Urashima Y; Yoshitake T; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Hiratsuka Y; Hirano T; Hanada K; Abe M; Fujisawa Y; Honda H
Anticancer Res; 2006; 26(3B):2367-74. PubMed ID: 16821618
[TBL] [Abstract][Full Text] [Related]
3. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
Zelefsky MJ; Kattan MW; Fearn P; Fearon BL; Stasi JP; Shippy AM; Scardino PT
Urology; 2007 Aug; 70(2):283-7. PubMed ID: 17826490
[TBL] [Abstract][Full Text] [Related]
5. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
[TBL] [Abstract][Full Text] [Related]
7. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
Jereczek-Fossa BA; Zerini D; Vavassori A; Fodor C; Santoro L; Minissale A; Cambria R; Cattani F; Garibaldi C; Serafini F; Matei VD; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):115-25. PubMed ID: 19004572
[TBL] [Abstract][Full Text] [Related]
8. Radical external beam radiotherapy for prostate cancer in Japan: results of the 1999-2001 patterns of care process survey.
Ogawa K; Nakamura K; Onishi H; Sasaki T; Koizumi M; Shioyama Y; Komiyama T; Miyabe Y; Teshima T;
Jpn J Clin Oncol; 2006 Jan; 36(1):40-5. PubMed ID: 16418185
[TBL] [Abstract][Full Text] [Related]
9. Postoperative radiotherapy for patients with prostate cancer in Japan; Changing trends in national practice between 1996-98 and 1999-2001: Patterns of care study for prostate cancer.
Sasaki T; Nakamura K; Ogawa K; Onishi H; Otani Y; Koizumi M; Shioyama Y; Teshima T;
Jpn J Clin Oncol; 2006 Oct; 36(10):649-54. PubMed ID: 16905754
[TBL] [Abstract][Full Text] [Related]
10. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
[TBL] [Abstract][Full Text] [Related]
11. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
12. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
Cozzarini C; Montorsi F; Fiorino C; Alongi F; Bolognesi A; Da Pozzo LF; Guazzoni G; Freschi M; Roscigno M; Scattoni V; Rigatti P; Di Muzio N
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):966-74. PubMed ID: 19619960
[TBL] [Abstract][Full Text] [Related]
13. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
14. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
[TBL] [Abstract][Full Text] [Related]
15. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.
King CR; Spiotto MT
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.
Truong PT; Berthelet E; Lee JC; Petersen R; Lim JT; Gaul CA; Pai H; Blood P; Ludgate CM
Can J Urol; 2006 Jun; 13(3):3139-46. PubMed ID: 16813705
[TBL] [Abstract][Full Text] [Related]
17. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
18. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
[TBL] [Abstract][Full Text] [Related]
20. [Salvage radiotherapy for pT3 prostate cancer with PSA failure after radical prostatectomy].
Wakita T; Hayashi N; Fuwa N
Hinyokika Kiyo; 2005 Sep; 51(9):575-80. PubMed ID: 16229369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
